A Three-Way Comparison of Tuberculin Skin Testing, QuantiFERON-TB Gold and T-SPOT.TB in Children

Tom G. Connell¹,²,³*, Nicole Ritz¹,²,³*, Georgia A. Paxton⁴, Jim P. Buttery¹,²,³, Nigel Curtis¹,²,³*, Sarath C. Ranganathan¹,²,⁵

¹ Department of Paediatrics, University of Melbourne, Royal Children’s Hospital Melbourne, Parkville, Victoria, Australia, ² Murdoch Children’s Research Institute, Royal Children’s Hospital Melbourne, Parkville, Victoria, Australia, ³ Infectious Diseases Unit, Department of General Medicine, Royal Children’s Hospital Melbourne, Parkville, Victoria, Australia, ⁴ Immigrant Health Service, Department of General Medicine, Royal Children’s Hospital Melbourne, Parkville, Victoria, Australia, ⁵ Department of Thoracic Medicine Royal Children’s Hospital Melbourne, Parkville, Victoria, Australia

Abstract

Background: There are limited data comparing the performance of the two commercially available interferon gamma release assays (IGRAs) for the diagnosis of tuberculosis (TB) in children. We compared QuantiFERON-TB gold In Tube (QFT-IT), T-SPOT.TB and the tuberculin skin test (TST) in children at risk for latent TB infection or TB disease.

Methods and Findings: The results of both IGRAs were compared with diagnosis assigned by TST-based criteria and assessed in relation to TB contact history. Results from the TST and at least one assay were available for 96 of 100 children. Agreement between QFT-IT and T-SPOT.TB was high (93% agreement, $\kappa = 0.83$). QFT-IT and T-SPOT.TB tests were positive in 8 (89%) and 9 (100%) children with suspected active TB disease. There was moderate agreement between TST and either QFT-IT (75%, $\kappa = 0.50$) or T-SPOT.TB (75%, $\kappa = 0.51$). Among 38 children with TST-defined latent TB infection, QFT-IT gold and T-SPOT.TB assays were positive in 47% and 39% respectively. Three TST-negative children were positive by at least one IGRA. Children with a TB contact were more likely than children without a TB contact to have a positive IGRA (QFT-IT LR 3.9; T-SPOT.TB LR 3.9) and a positive TST (LR 1.4). Multivariate linear regression analysis showed that the magnitude of both TST induration and IGRA IFN-γ responses was significantly influenced by TB contact history, but only the TST was influenced by age.

Conclusions: Although a high level of agreement between the IGRAs was observed, they are commonly discordant with the TST. The correct interpretation of a negative assay in a child with a positive skin test in clinical practice remains challenging and highlights the need for longitudinal studies to determine the negative predictive value of IGRAs.

Introduction

The detection and treatment of latent tuberculosis (TB) infection is a key strategy in the control of TB [1,2]. Improved methods for detecting both latent TB infection and TB disease in children are needed. Interferon gamma release assays (IGRAs) incorporating Mycobacterium tuberculosis (MTB)-specific antigens have emerged as potential replacements for the century old tuberculin skin test (TST) [3]. IGRAs have been shown to have high sensitivity and specificity in adults [4] but there are few studies that have assessed their performance for the diagnosis of latent TB infection or TB disease specifically in children [5]. A recent meta-analysis highlighted an urgent need for more evidence for the use of IGRAs for the diagnosis of latent TB infection in children [6]. The aim of this study was to compare the performance of two commercial IGRAs with TST in the diagnosis of children at risk for latent TB infection or with suspected active TB disease at a tertiary paediatric hospital.

Methods

Patients and inclusion criteria

The study was approved by the Human Research and Ethics Committee of the Royal Children’s Hospital Melbourne. Patients were recruited prospectively from the hospital’s TB, refugee health and infectious diseases clinics. Children at risk of latent TB infection or with suspected active TB disease were eligible for inclusion. At risk was defined as a recent TB contact and/or recent immigration from a country with a high prevalence of TB. Written informed consent was obtained from parents or participants in their preferred language. Demographic and clinical details were obtained from each patient by a detailed questionnaire, including: country and date of birth; TB exposure history; Bacille Calmette-Guérin (BCG) vaccination history; presence of BCG scar and symptoms suggestive of TB. All patients had a full clinical evaluation, a TST and blood tests including IGRA, full blood count and CD4 lymphocyte count. HIV tests were not done as part of this study.

Citation: Connell TG, Ritz N, Paxton GA, Buttery JB, Curtis N, et al. (2008) A Three-Way Comparison of Tuberculin Skin Testing, QuantiFERON-TB Gold and T-SPOT.TB in Children. PLoS ONE 3(7): e2624. doi:10.1371/journal.pone.0002624

Editor: Keertan Dheda, University College London, United Kingdom

Received April 4, 2008; Accepted June 6, 2008; Published July 9, 2008

Copyright: © 2008 Connell et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This project was supported by a grant from the John Burge Trust Victoria. Tom G Connell is supported by fellowship awards from the European Society of Paediatric Infectious Diseases and the Nossal. Institute of Global Health. Nicole Ritz is supported by fellowship awards from the Swiss National Science Foundation and the European Society of Paediatric Infectious Diseases. Funding bodies had no role in data analysis or in the preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: nigel.curtis@rch.org.au

These authors contributed equally to this work.
**Tuberculin skin test**

A Mantoux test was performed by intradermal injection of 10 international units tuberculin (Purified Protein Derivative (PPD) 100 IU/mL, CSL, Melbourne, Australia), the standard dose of tuberculin PPD used in Australia at the time of the study, by trained personnel and read after 48 to 72 hours. An assessment of the level of risk for TB infection was taken into consideration when defining the result of the TST, as recommended by recently modified local guidelines (Victorian Department of Human Services). A positive TST was defined as $\geq 10$ mm in patients with moderate risk factors (origin from high prevalence country; age 1 to 5 years); and $\geq 5$ mm in patients with high risk factors (household TB contact; age less than 1 year). If BCG was given within five years prior to the TST, the TST was considered positive if induration was $\geq 15$ mm in moderate risk patients and $\geq 10$ mm in high risk patients. In children with suspected active TB disease, TST induration $\geq 5$ mm was considered positive. Victorian guidelines for TST interpretation are similar to those of the American Thoracic Society (ATS), except that the potential influence of prior BCG is taken into consideration. Chest radiography was undertaken in those with a positive TST or when clinically indicated, and reported by radiologists who were blinded to the results of the IGRAs for each patient. Children deemed to have latent TB infection were offered isoniazid preventive treatment.

**Interferon gamma release assays**

A whole blood assay, QuantiFERON-TB gold In-Tube (QFT-IT), Cellestis Ltd, Australia and an enzyme-linked immunospot assay (ELISPOT), T-SPOT.TB, Oxford Immunotec, Oxford, UK were carried out according to the manufacturers’ guidelines and were defined as positive, negative or indeterminate based on manufacturers’ recommended criteria. The laboratory scientists undertaking the IGRAs were blinded to the clinical status of the patients. The QFT-IT (3rd generation) assay incorporates an additional MTB-specific antigen TB 7.7 in addition to ESAT-6 and CFP-10. This assay was undertaken at the Victorian Infectious Disease Reference Laboratory Melbourne (VIDRL). The T-SPOT. TB test was undertaken in the Microbiology Research Laboratory at the Royal Children’s Hospital Melbourne. Spots were counted with a magnifying glass and expressed as spots per million peripheral blood mononuclear cells (PBMC). Two further independent observers, also blinded to clinical status allocation, confirmed spot counts and assigned results.

**Definitions**

*Latent TB infection* was defined as an asymptomatic child with a positive TST and chest radiograph not suggestive of TB. *Active TB disease* was defined as a child with a positive TST with symptoms suggestive of TB and/or an abnormal chest radiograph consistent with TB, or a child with MTB cultured from clinical specimens. Symptoms considered suggestive of TB included the following: cough for more than two weeks, persistent fever, night sweats and weight loss. *Uninfected* was defined as a well child with a negative TST and chest radiograph not suggestive of TB but in whom results of all investigations for TB were negative or a child with an alternative diagnosis and complete recovery in the absence of specific TB treatment.

**Statistics**

Data were analysed using Prism Graphpad (Version 5). Nonparametric unpaired data (TST indurations) were analysed by the Mann-Whitney U test. The mean age of children was compared using an unpaired t test or one-way anova. A Fisher’s exact or chi-square test was used to compare proportions when the results of IGRAs were analysed as dichotomous outcomes, and an unpaired t test was used when IGRA antigen responses were analysed as continuous measures. Agreement between TST and IGRAs was assessed by the kappa statistic [7]. A multivariate linear regression model was used to determine the influence of age, BCG scar, origin from country with high TB prevalence and TB contact on the results of TST and IGRAs. Correlations were assessed using the Spearman’s correlation coefficient.

**Results**

Clinical and demographic details are shown in Table 1. Of 101 children enrolled in the study, four (4%) failed to return for a TST.

| Table 1. Demographic, clinical and laboratory details of study participants. |
|---------------------------------|----------------|----------------|
|                                | Latent TB | TB disease |
| (n = 38)                        | (n = 9)    | (n = 49)    |
| **Demographic**                 |           |             |
| Mean age in years (range)       | 10.2 (0.7–18.8) | 8.2 (1.8–13.6) | 8.4 (0.5–19.0) |
| Male                            | 17 (45%)  | 5 (55%)     | 28 (57%) |
| Born in high TB prevalence area | 30 (79%)  | 8 (89%)     | 43 (88%) |
| **TB contact**                  |           |             |
| Household                       | 16 (42%)  | 8 (89%)     | 10 (20%) |
| Non-household                   | 6 (16%)   | 1 (11%)     | 1 (2%)  |
| No known contact                | 16 (42%)  | 0            | 38 (78%) |
| **Clinical**                    |           |             |
| TB symptoms                     | 1 (3%)    | 6 (67%)     | 3 (6%)  |
| BCG                             |           |             |
| Scar present                    | 23 (61%)  | 1 (11%)     | 24 (43%) |
| History but no scar             | 2 (5%)    | 1 (11%)     | 3 (6%)  |
| No evidence of prior BCG        | 13 (34%)  | 7 (78%)     | 20 (41%) |
| Presence/absence of scar not recorded | 6 (12%) |             |         |
| **Tuberculin skin test**        |           |             |
| 0–4 mm                          | 0          | 0           | 40 (82%) |
| 5–9 mm                          | 3 (8%)     | 1 (11%)     | 8 (16%) |
| 10–14 mm                        | 12 (32%)   | 0           | 1 (2%)  |
| $\geq15$ mm                     | 23 (60%)   | 7 (78%)     | 0       |
| Induration median (range)       | 15 (8–37) | 21 (6–24)   | 0 (0–10) |
| **Chest radiograph**            |           |             |
| Normal                          | 35 (92%)  | 1 (11%)$^\dagger$ | 19 (39%) |
| Abnormal                        | 2 (5%)$^\ddagger$ | 8 (89%) | 1 (2%)$^\dagger$ |
| Not done/ unavailable           | 1 (3%)$^\dagger$ | 0            | 29 (59%) |
| **Laboratory**                  |           |             |
| CD4 median (IQR)                | 40% (38–52%) | 43% (30–56%) | 40% (35–52%) |

$^\dagger$Final diagnosis: *Streptococcus pneumoniae* pneumonia; cough $\geq$ 2 weeks; sputum samples AFB negative.

$^\ddagger$One child with TB disease did not have a TST.

$^\dagger$Extrapulmonary TB.

*One child with evidence of prior TB; one child with right upper lobe opacification ($K$. pneumoniae on culture).

*Right upper lobe opacification (culture negative).*

*Well, asymptomatic child; failed to attend for follow up CXR.*

$^{CD4}$CD4 count available for 82 children.

doi:10.1371/journal.pone.0002624.001
reading and could not be categorized according to the study criteria. *Mycobacterium gordanae* was cultured from the sputum of one child, who was subsequently excluded from further analysis. Of the remaining 96 children, 82 (85%) originated from a high TB prevalence country. On the basis of pre-defined criteria for categorizing patients to diagnostic groups, 38 (40%) children had latent TB infection, 9 (9%) TB disease and 49 (51%) were uninfected. The mean age of the children in the three groups was not significantly different (p = 0.19). No child had a clinical presentation consistent with HIV infection and all children had a CD4% within the normal range for age.

The agreement between observers for the T-SPOT.*TB* assay results was high (interobserver reliability 96%). In four tests there was a discrepancy in assigning a result (one observer positive, two observers negative in each instance) with all four finally deemed negative by consensus. Although there were more indeterminate results with the T-SPOT.*TB* assay than with the QFT-IT assay overall (14/96 vs. 3/96, p = 0.009), the majority of indeterminate results for the T-SPOT.*TB* assay were attributable to potential laboratory error (Tables 2 and 3). Specifically, of the 14 indeterminate T-SPOT.*TB* assays, inadequate PBMC separation accounted for seven and cross-contamination occurred in two assays. Excluding these nine assays, the difference in the proportion of ‘true’ indeterminate results between the two assays was not statistically significant (3/96 vs. 5/87, p = 0.48).

The proportion of indeterminate results for both IGRA was higher in children younger than three years of age compared to those older than three years of age. Specifically, of 16 children younger than three years of age, two (12.5%) had an indeterminate QFT-IT assay result (one inadequate mitogen control, one high nil control) compared to one (1.1%) indeterminate result (inadequate mitogen control) in the 84 children older than three years of age (p = 0.06). Similarly, of the 16 children younger than three years of age, five (31.3%) had an indeterminate T.SPOT.TB assay result (four inadequate PBMC, one technical) compared to nine (10.7%) indeterminate results (three high nil control, two inadequate PBMC, two technical, two cross contamination) in the 84 children older than three years of age (p = 0.05).

When the assays both yielded interpretable (ie non-indeterminate) results, the overall agreement between QFT-IT and T-SPOT.*TB* was high (93% agreement, $\kappa = 0.83$, 95% CI 0.65–0.91). However, the results between the two IGRA were discordant in six children (Table 3). Results were QFT-IT positive / T-SPOT.*TB* negative in four children (two with household TB contact and positive TST of

| Table 2. Results of QuantiFERON-TB gold in-Tube and T-SPOT.*TB* assays in each diagnostic category. |
|---------------------------------------------------------------|
| **QuantiFERON-TB gold in-Tube** | **T-SPOT.*TB*** |
| Positive | Negative | Indeterminate | Positive | Negative | Indeterminate |
| All patients (n = 100) |  |  |  |  |  |
| Latent TB (n = 38) | 18 (47%) | 20 (53%) | (0) | 15 (39%) | 19 (50%) | 4 (10%)* |
| TB disease (n = 9) | 8 (89%) | 1 (11%) | 0 | 9 (100%) | 0 | 0 |
| Uninfected (n = 49) | 2 (4%) | 44 (90%) | 3 (6%)† | 1 (2%) | 38 (78%) | 10 (20%)‡ |
| No TST result (n = 4) | 1 (25%) | 3 (75%) | 0 | 0 | 4 (100%) | 0 |
| Patients with TB contact (n = 44) |  |  |  |  |  |
| Latent TB (n = 22) | 13 (59%) | 9 (41%) | 0 | 10 (46%) | 10 (46%) | 2 (9%)$^*$ |
| TB disease (n = 9) | 8 (89%) | 1 (11%) | 0 | 9 (100%) | 0 | 0 |
| Uninfected (n = 11) | 1 (9%) | 8 (73%) | 2 (18%)$^*$ | 1 (9%) | 5 (45%) | 5 (45%)** |
| No TST result (n = 2) | 1 (50%) | 1 (50%) | 0 | 0 | 2 (100%) | 0 |

*3 inadequate PBMC; 1 cross contamination.
†1 high nil control; 2 inadequate mitogen control.
‡3 high nil control; 4 inadequate PBMC; 2 technical; 1 cross contamination.
$^*$1 inadequate PBMC; 1 cross contamination.
**1 inadequate mitogen control; 1 high nil control.

*Includes children where TST result was unavailable.

$\kappa$ (95% CI) for agreement between T-SPOT.TB and QuantiFERON-TB gold In-Tube in all patients was 0.83 (0.65–0.91) and in patients with latent TB infection was 0.82 (0.54–0.92).

doi:10.1371/journal.pone.0002624.t002

| Table 3. Comparison of the results of QuantiFERON-TB gold in-Tube and T-SPOT.*TB* assays. |
|---------------------------------------------------------------|
| **QuantiFERON-TB gold in-Tube** | **T-SPOT.*TB*** |
| Positive | Negative | Indeterminate | Positive | Negative | Indeterminate |
| T-SPOT.TB |  |  |  |  |  |
| All patients (n = 100)* | 22 (22%) | 2 (2%) | 1 (1%) | 15 (39%) | 19 (50%) | 4 (10%)* |
| Positive | 4 (4%)* | 56 (55%)* | 1 (1%) |
| Negative | 3 (3%) | 10 (10%) | 1 (1%) |
| Indeterminate | 14 (37%) | 1 (3%) | 0 |
| Patients with latent TB infection (n = 38) |  |  |  |  |  |
| Positive | 2 (5%) | 17 (45%) | 0 |
| Negative | 2 (5%) | 2 (5%) | 0 |

*Includes children where TST result was unavailable.

$\kappa$ (95% CI) for agreement between T-SPOT.TB and QuantiFERON-TB gold In-Tube in all patients was 0.83 (0.65–0.91) and in patients with latent TB infection was 0.82 (0.54–0.92).

doi:10.1371/journal.pone.0002624.t003
Seven of these children had a TST induration (45%) of the 38 children with TST-defined latent TB infection. To 19/38 (50%). The results of both IGRAs were negative in 17 infection compared to QFT-IT alone, increasing the detection rate detected only one additional patient with TST-defined latent TB infection (Table 2). Combining results from both IGRAs assay was positive in 15 (39%) of the 38 children with TST-defined latent TB infection (Table 2). Combining results from both IGRAs.

These comprised a 9-year old (QFT-IT positive / T-SPOT.TB negative) from a high TB prevalence country with no known TB contact; and a 2-year old (QFT-IT indeterminate / T-SPOT.TB positive) with no prior BCG immunisation, who was a household TB contact. Of the children with TB disease, results of the QFT-IT and T-SPOT.TB tests were positive in 8 (89%) and 9 (100%) children respectively.

The responses to the MTB-specific antigens for both IGRAs are shown in Figure 2. In the T-SPOT.TB assay, the mean (SEM) IFN-γ response to ESAT-6 and CFP-10 was higher in children with TB disease compared to those with latent TB infection (ESAT-6 396 (125.7) vs. 173.3 (51.1) spot forming cells per million PBMC (SFC/10^6), p = 0.07; CFP-10 421.3 (146.2) vs. 136.5 (35.6) SFC/10^6, p = 0.007). Similarly the IFN-γ response to ESAT-6 and CFP-10 was higher in children with latent TB infection compared to uninfected children (ESAT-6 173.3 (51.1) vs. 14.7 (10.4) SFCs/10^6, p = 0.001; CFP-10 136.5 (35.6) vs. 10.4 (5.6) SFCs/10^6, p = 0.0004). In the QFT-IT assay mean (SEM) IFN-γ responses to ESAT-6, CFP-10 and TB 7.7 were also significantly higher in children with TB disease compared to those with latent TB infection (12.44 (1.9) vs. 4.65 (1.06) IU/mL, p = 0.002). Similarly, children with latent TB infection had significantly higher mean IFN-γ responses than uninfected children (4.65 (1.06) vs. 0.06 (0.03) IU/mL, p<0.0001).

The influence of age, BCG scar, origin from country with high TB prevalence and TB contact on the results of TST and IGRAs was assessed. There was no significant difference in the median TST induration between BCG-immunised and BCG-non-immunised children overall or within the subgroup of children with latent TB infection (all children with TST >0 mm (n = 55): 13 mm vs. 17 mm; p = 0.25; children with latent TB infection (n = 38): 15 mm vs. 17 mm; p = 0.47). Among the 87 children with latent TB infection or who were uninfected, the mean age of those with a positive or negative QFT-IT (10.3 vs 9.2 years, p = 0.4) or T-SPOT.TB (10.3 vs 9.5 years, p = 0.54) assay was similar. Children with a TB contact were more likely than those without a TB contact to have a positive TST, a positive QFT-IT and a positive T-SPOT.TB (Table 5).

In a multivariate linear regression analysis, age (p = 0.03) and TB contact (p<0.0001), but not BCG scar (p = 0.86) or origin from a country with high TB prevalence (p = 0.30), were significantly correlated with the magnitude of TST induration. In contrast, the only factor that significantly influenced the magnitude of the IFN-γ response in the IGRAs was TB contact (QFT-IT and T-SPOT.TB, p<0.0001). The proportion of children with a TB contact who had a positive TST (at both a 5 mm and a 10 mm cut-off) was higher than the proportion with a

**Table 4.** Details of the results from children with latent TB infection and negative QuantiFERON-TB gold in tube or T-SPOT.TB results.

| IGRA result | TST induration (mm) |
|-------------|---------------------|
|             | ≥5 to 9 | ≥10 to 14 | ≥15 |
| QFT-IT      | T-SPOT.TB |
| All patients with latent TB infection (n = 22) | Negative | (1 positive) | 3 (2) | 7 (2) | 10 (3) |
|             | (2 positive) | Negative | 3 (2) | 9 (2) | 7 (3) |
| Patients with latent TB infection and TB contact (n = 11) | Both negative | 3 (2) | 7 (2) | 7 (3) |
|             | Either negative | 3 (2) | 9 (2) | 10 (3) |
|             | Either negative | 3 (2) | 4 (2) | 4 (1) |
positive IGRA indicating a higher sensitivity for the TST in this setting (Table 5). In contrast, the IGRA appeared to be more specific (with respect to TB contact) than the TST.

**Discussion**

This is the largest study to date to compare the two currently available commercial IGRA with TST for the diagnosis of latent TB infection specifically in children. The level of agreement between QFT-IT and T-SPOT.TB in our study ($k = 0.83$) was higher than that observed in the studies by Arend et al ($k = 0.59$) [8] and Leyten et al [9] ($k = 0.71$). The infrequent occurrence of discordant results between the IGRA suggests that either assay can be used depending on resources and availability. However, there was significant discordance between the results of TST and both IGRA. This is important because IGRA are increasingly considered potential replacements for TST for the detection of latent TB infection [10,11]. Specifically, of 38 children with TST-defined latent TB infection, less than half had a positive QFT-IT or T-SPOT.TB. A critical question, with important implications for the future use and interpretation of IGRA, is whether this is the result of false positive TST or false negative IGRA results [12].

Several studies have questioned the sensitivity of IGRA [8,13,14,15,16,17,18,19,20]. We previously found poor agreement between QFT-TB Gold (an earlier 2nd generation QuantiFERON assay) and TST (k = 0.3) for the diagnosis of latent TB infection [14]. In our previous study, a high proportion of children with a household TB contact positive by TST were negative by QFT-TB Gold and the assay was negative in almost half of the children with a TST $\geq 15$ mm. Compared with our previous study, we found better agreement between TST and both QFT-IT and T-SPOT.TB although it is not clear whether this is clinically significant. For the QFT-IT assay, better agreement may be explained by the incorporation of an additional MTB-specific antigen (TB 7.7) conferring increased sensitivity [18]. However, the sensitivity of IGRA for the detection of latent TB infection in children remains questionable with our finding that in children with TST indurations $\geq 15$ mm who had latent TB infection, only 13/23 (57%) QFT-IT

### Table 5. The influence of TB contact on TST, QFT-IT and T-SPOT.TB results for the 87 children with latent TB infection (n = 38) or who were uninfected (n = 49).

| TB contact | Proportion positive with TB contact | Proportion negative without TB contact | LR (95% CI) |
|------------|------------------------------------|---------------------------------------|-------------|
| TST (cut off $\geq 5$ mm) | Pos 22 | 22/33 (67%) | 29/54 (54%) | 1.4 (0.98–2.0) |
|           | Neg 11 | 29 | 29/54 (54%) | 1.4 (0.98–2.0) |
| TST (cut off $\geq 10$ mm) | Pos 19 | 19/33 (58%) | 37/54 (68%) | 1.8 (1.1–2.8) |
|           | Neg 14 | 37 | 37/54 (68%) | 1.8 (1.1–2.8) |
| TST (cut off $\geq 15$ mm) | Pos 13 | 13/33 (39%) | 44/54 (81%) | 2.1 (1.0–4.2) |
|           | Neg 20 | 44 | 44/54 (81%) | 2.1 (1.0–4.2) |
| QFT-IT    | Pos 14 | 14/31 (45%) | 47/53 (89%) | 3.9 (1.8–9.2) |
|           | Neg 17 | 47 | 47/53 (89%) | 3.9 (1.8–9.2) |
| T-SPOT.TB | Pos 11 | 11/26 (42%) | 42/47 (89%) | 3.9 (1.6–10.0) |
|           | Neg 15 | 42 | 42/47 (89%) | 3.9 (1.6–10.0) |
assays and 12/19 (63%) T-SPOT.TB assays were positive (Figure 3). Furthermore, in the 22 children with TST-defined latent TB infection with either a negative QFT-IT or a negative T-SPOT.TB result, almost a third had a TB contact and almost half had a TST $\geq 15$ mm and, importantly, discordant results occurred even in the absence of BCG vaccination. Of note, there were three children (including one without prior BCG vaccination) with a TB contact and TST $\geq 15$ mm in whom the results of both IGRAs were negative.

Our results are consistent with a recent large TB contact investigation in non-BCG vaccinated adults in which the QFT-IT and T-SPOT.TB assays were positive in only 42% and 51% respectively of those with a TST induration $\geq 15$ mm [8]. Similarly, in another recent study, less than half of immigrants with a TST induration $\geq 15$ mm were positive by QFT-TB Gold and the overall agreement between TST and QFT-TB Gold was poor ($k = 0.37$) [21]. Another study in adults showed poor agreement between QFT-IT, an ELISPOT assay and a 6 day lymphocyte-stimulation assay [9]. Of 27 TST positive adults (mean induration 16 mm), 9 (33%) and 11 (46%) individuals tested positive by QFT-IT and ELISPOT respectively. One explanation for these results as well as the findings in our study is that discordant results are due to superior sensitivity of TST for the detection of latent TB infection revealing ‘false negative’ IGRA. However, the finding of three children in our study (two with a household TB contact) with a negative TST and at least one positive IGRA appears to be inconsistent with this explanation.

The alternate explanation for discordant TST and IGRA results is that IGRAs have superior specificity and reveal ‘false positive’ TST results [22,23,24]. The lack of a gold standard for latent TB infection is a recognised inherent limitation of all studies that investigate the use of IGRAs for the detection of latent TB infection. Therefore estimating the sensitivity of any new test for latent TB infection is problematic. In the absence of a recognised gold standard, analysis of results with respect to TB contact history is one way to infer potential superiority of one test over another for the detection of latent TB infection. Although it is recognised that not all individuals exposed to a smear positive TB contact will subsequently become infected, this has become an accepted ‘gold standard’ on which to base comparative evaluations. Our findings that IGRAs have higher specificity than TST at any cut off with respect to TB contact history is consistent with the possibility that IGRAs have superior specificity for the detection of children with ‘true’ latent TB infection.

There are at least four further potential explanations for discordance between TST and IGRAs results. Firstly, in contrast to the TST which remains positive for a protracted period after past or cleared MTB infection [8,25] recent evidence suggests that QFT-IT and T-SPOT.TB assays detect more recent or ongoing infection [26,27]. This may be because the IGRAs predominantly detect effector MTB-specific T cells in an overnight stimulation assay whereas TST induration is measured at 48–72 hours allowing for the expansion of memory T cell populations [8,13]. Interestingly a 6-day lymphocyte-stimulation test correlated better with TST than overnight IGRA in one study [9]. Secondly, IGRAs may revert to negative following clearance of TB infection [28]. Thirdly, prior sensitisation by non-tuberculosis mycobacteria, which is common in high TB prevalence countries, could lead to false positive TST results in some patients. In a recent study, 24% of children with non-tuberculosis mycobacteria had TST indurations $>15$ mm [29] and TST indurations $>20$ mm have been reported in this setting [30]. Lastly, the dose of the tuberculin PPD used in skin test reagents worldwide is not standardised. Though unlikely, the standard use of 10 IU of tuberculin PPD in Australia at the time of the study potentially resulted in more ‘false positive’ TST results.

The correct interpretation of a negative IGRA in a patient with a positive TST in routine clinical practice is challenging, particularly if the patient has a documented TB contact. In the absence of definitive evidence to confirm that discordant results are attributable to false positive TST results, our current practice is to offer isoniazid preventive treatment irrespective of IGRA result. However, a recent Japanese high school TB contact investigation provides preliminary evidence for withholding preventive treatment in individuals with TST positive / IGRA negative results [31]. Of 349 students in this study, 95 had a positive TST (defined as erythema $\geq 30$ mm in those with prior BCG and contact with smear positive index case) of whom only four had a positive QFT-TB Gold assay result. Preventive treatment was offered to these four only, significantly reducing the number of students in whom chemoprophylaxis was prescribed. Importantly, no student has subsequently developed TB disease during a three and a half year follow up. However, this study had a relatively short follow up and does not address the issue of discordant results in young children in whom the risk of progression to TB disease may be higher. Also, until recently, it was not uncommon for individuals in Japan to have multiple BCG immunisations, potentially increasing the magnitude of TST responses. In addition, the measurement of erythema in defining a positive TST is unique to Japan and questions the applicability of these findings in countries where the measurement of induration is standard, despite limited evidence that there is good correlation between erythema and induration [32]. Therefore, before this approach can be considered safe, further, larger studies with longer follow-up are needed to
investigate the natural history of children with TST positive / IGRA negative results and their risk of developing TB disease. Despite this, the UK National Institute for Clinical Excellence guidelines for the management of latent TB infection already recommend withholding preventive treatment in children over two years of age with a positive TST in whom the result of an IGRA is negative [33].

The higher rate of indeterminate results in the T-SPOT TB assay compared with QFT-IT was attributable to a number of factors. The T-SPOT TB is operationally more complex than the QFT-IT and 9 of the 14 indeterminate T-SPOT TB results were attributable to potential laboratory error. The laboratory scientist undertaking the T-SPOT TB assay underwent specific training prior to the study but given the relative complexity of the assay and the number of processing steps, the chance of a laboratory error occurring seems to be higher for the T-SPOT TB assay. The indeterminate results potentially attributable to laboratory error were included in our analysis as they reflect real world practice. However, indeterminate results have been reported less frequently in the T-SPOT TB assay than the QFT-IT assay in other studies [34]. The proportion of indeterminate QFT-IT assays was significantly less than the 17% reported in our previous study (p<0.001), the majority of which were due to a high nil control response [14,35]. In the present study only one assay had a high nil control response as defined by the manufacturer’s latest guidelines for test interpretation that allow a significantly higher background nil control response of up to 8 IU/mL. In our current study, 14% of children had a background IFN-γ response ≥ 1 IU/ml and 6% had a background ≥ 2 IU/mL. Several other studies have reported assays with high nil control responses [19,36]. We have previously highlighted our concern about the validity of reporting assays with background levels ≥ 2 IU/mL [35]. For the T-SPOT TB assay, four had background nil control responses ≥ 40 SFCs/10⁶. The cause of high nil control responses in IGRA warrants further investigation.

In conclusion we have shown high agreement between QFT-IT and T-SPOT TB in children. Discordant results between TST and IGRAxs are common (most often TST positive, IGRA negative) and highlight the need for further longitudinal studies to determine the negative predictive value of IGRAxs and the validity of current recommendations for the investigation and treatment of latent TB infection in children.

Acknowledgments

We thank Bindu Bali, Andrea Smith, Kate Thompson, and Barry Linnane for their assistance in patient recruitment to this study. We thank Rosemary Carzino for undertaking the T-SPOT TB assays. We thank David Leslie and Norbert Ryan for helpful discussions. We are grateful to Marc Terheuge for helpful comments on the manuscript. We also thank all the families for participating in this study.

Author Contributions

Conceived and designed the experiments: SR TGC NC NR JPB. Performed the experiments: NR. Analyzed the data: SR TGC NC NR GAP JPB. Contributed reagents/materials/analysis tools: SR NC. Wrote the paper: SR TGC NC NR GAP JPB. Performed experiments with laboratory scientist: NR. Wrote the first draft of the manuscript: TC. Enrolled patients: TC NR GP JBR SR.

References

1. (2000) Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 161: S221–247.
2. Snieja M, Marchetti CA, Cook DJ, Smaill FM (2000) Ionizing for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev: CD001363.
3. Pai M, Kalani C, Dheda K (2006) New tools and emerging technologies for the diagnosis of tuberculosis: Part I. Latent tuberculosis. Expert Rev Mol Diagn 6: 413–422.
4. Richeldi L (2006) An update on the diagnosis of tuberculosis infection. Am J Respir Crit Care Med 174: 736–743.
5. Pai M, Dheda K, Cunningham J, Scano F, O'Brien R (2007) T-cell assays for the diagnosis of latent tuberculosis infection: moving the research agenda forward. Lancet Infect Dis 7: 428–438.
6. Menzies D, M P, Comstock G (2007) Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 146: 340–354.
7. Land J, Koch G (1977) The measurement of observer agreement for categorical data. Biometrics 33: 159–174.
8. Arend SM, Thijsen SF, Leyten EM, Bouwman JJ, Franken WP, et al. (2007) Comparison of two interferon-gamma assays and tuberculin skin test for tracing tuberculosis contacts. Am J Respir Crit Care Med 175: 619–627.
9. Leyten EM, Arend SM, Prins C, Cobelo GF, Ottenhoff TH, et al. (2007) Discrepancy between Mycobacterium tuberculosis-specific interferon-(gamma)- release assays using short versus prolonged in vitro incubation. Clin Vaccine Immunol.
10. Latvala A (2007) Diagnosing tuberculosis in the 21st century: new tools to tackle an old enemy. Chest 131: 1896–1906.
11. Mauer Z, Herberg J, Lobue P, Ladenrnan MF, Metchock B, et al. (2005) Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 54: 49–55.
12. Pai M, Menzies D (2007) The new IGRA and the old TST: making good use of disagreement. Am J Respir Crit Care Med 175: 529–531.
13. Gehovin A, Cliff JM, Hill PC, Brookes RH, Dockrell HM (2007). Extended culture enhances sensitivity of a gamma interferon assay for latent Mycobacterium tuberculosis infection. Clin Vaccine Immunol 14: 796–798.
14. Connell TG, Curtis N, Ranganathan SC, Buttery JP (2006) Performance of a whole blood interferon gamma assay for detecting latent infection with Mycobacterium tuberculosis in children. Thorax 61: 616–620.
15. Dewan PK, Grinsdale J, Kawamura LM (2007) Low sensitivity of a whole-blood interferon-gamma release assay for detection of active tuberculosis. Clin Infect Dis 44: 69–73.
16. Ferrara G, Losi M, Mercati M, Messenga B, Piero R, et al. (2005) Routine Hospital Use of a New Commercial Whole Blood Interferon-gamma Assay for the Diagnosis of Tuberculosis Infection. Am J Respir Crit Care Med 172: 631–635.
17. Hill PC, Brookes RH, AridetaIMO, Fox A, Jackson-Sillah D, et al. (2006) Comparison of Enzyme-Linked Immunosassay and Tuberulin Skin Test in Healthy Children Exposed to Myobacterium tuberculosis. Pediatrics 117: 1542–1548.
18. Mahomed H, Hughes EJ, Hawinkude T, Minnies D, Simon E, et al. (2006) Comparison of manuous skin test with three generations of a whole blood IFN-γ assay for tuberculosis infection. Int J Tuberculosis Lung Dis 10: 310–316.
19. Mauer Z, Weis SE, Moonan PK, Daley CL, Bernardo J, et al. (2007) Prospective comparison of the tuberculin skin test and 2 whole-blood interferon-gamma release assays in persons with suspected tuberculosis. Clin Infect Dis 45: 837–845.
20. Mauer Z, Zajkowicz M, Hankinson AL, Costigan DJ, Toney SR, et al. (2007) Detection of Mycobacterium tuberculosis infection in United States Navy recruits using the tuberculin skin test or whole-blood interferon-gamma release assays. Clin Infect Dis 45: 926–936.
21. Carvalho AC, Pezzoli MC, El-Hamad I, Arce P, Bigoni S, et al. (2007) QuantiFERON-TB Gold test in the identification of latent tuberculosis infection in immigrants. J Infect 55: 164–168.
22. Ever K, Deeks J, Alvarez L, Bryant G, Waller S, et al. (2003) Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet 361: 1168–1173.
23. Harada N, Nakajima Y, Higuchi K, Sekiya Y, Rothel J, et al. (2006) Screening for Tuberculosis Infection Using Whole-Blood Interferon-gamma and Mantoux Testing Among Japanese Healthcare Workers. Infect Control Hosp Epidemiol 27: 442–448.
24. Latvala A, Paslaw AA, Durkan H, Wilkinson KA, Whelan A, et al. (2007) Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Lancet 357: 2017–2021.
25. Menzies D (1999) Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Care Med 159: 15–21.
26. Mori T, Harada N, Higuchi K, Sekiya Y, Uchimura K, et al. (2007) Waning of the specific interferon-gamma response after years of tuberculosis infection. Int J Tuberculosis Lung Dis 11: 1021–1023.
27. Suzuki K, Onozaki I, Shimura N, Harada N, Mori T (2004) QuantiFERON-TB-2nd Generation in the elderly persons. Kekkaku 79: 200.
28. Hill PC, Brookes RH, Fox A, Jackson-Sillah D, Jeffries DJ, et al. (2007) Longitudinal assessment of an ELISPOT test for Mycobacrerium tuberculosis infection. PLoS Med 4: e192.

29. Detjen AK, Keil T, Roll S, Hauer B, Mauch H, et al. (2007) Interferon-gamma release assays improve the diagnosis of tuberculosis and nontuberculous mycobacterial disease in children in a country with a low incidence of tuberculosis. Clin Infect Dis 45: 322–328.

30. Haimi-Cohen Y, Zebaria A, Mineeni M, Soukhman M, Amir J (2001) Skin indurations in response to tuberculin testing in patients with nontuberculous mycobacterial lymphadenitis. Clin Infect Dis 33: 1786–1788.

31. Higuchi K, Harada N, Mori T, Sekiya Y (2007) Use of QuantiFERON-TB Gold to investigate tuberculosis contacts in a high school. Respiratory 12: 88–92.

32. Kimura M, Comstock GW, Mori T (2005) Comparison of erythema and induration as results of tuberculin tests. Int J Tuberc Lung Dis 9: 853–857.

33. Taylor RE, Cant AJ, Clark JE (2007) Potential impact of NICE tuberculosis guidelines in paediatric TB screening. Arch Dis Child.

34. Ferrara G, Losi M, D’Amico R, Roversi P, Piro R, et al. (2006) Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 367: 1329–1334.

35. Curtis N, Connell T, Buttery JP, Ranganathan S (2006) Whole blood IFN-gamma assay for detecting TB in children. author reply. Thorax 61: 920–921.

36. Nakaoka H, Lawson L, Bertel Squire S, Coulter B, Ravn P, et al. (2006) Risk for Tuberculosis among children. Emerg Infect Dis 12: 1383–1388.
Author/s: 
Connell, TG; Ritz, N; Paxton, GA; Buttery, JP; Curtis, N; Ranganathan, SC

Title: 
A Three-Way Comparison of Tuberculin Skin Testing, QuantiFERON-TB Gold and T-SPOT. TB in Children

Date: 
2008-07-09

Citation: 
Connell, T. G., Ritz, N., Paxton, G. A., Buttery, J. P., Curtis, N. & Ranganathan, S. C. (2008). A Three-Way Comparison of Tuberculin Skin Testing, QuantiFERON-TB Gold and T-SPOT. TB in Children. PLOS ONE, 3 (7), https://doi.org/10.1371/journal.pone.0002624.

Persistent Link: 
http://hdl.handle.net/11343/242677

File Description: 
published version

License: 
CC BY